These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 16920570

  • 1. Treatment of rheumatoid arthritis with rituximab: an update and possible indications.
    De Vita S, Quartuccio L.
    Autoimmun Rev; 2006 Aug; 5(7):443-8. PubMed ID: 16920570
    [Abstract] [Full Text] [Related]

  • 2. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L, Lombardi S, Fabris M, Masolini P, Saracco M, Pellerito R, De Vita S.
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [Abstract] [Full Text] [Related]

  • 3. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R, Caprioli M, Bobbio-Pallavicini F, Bugatti S, Montecucco C.
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [Abstract] [Full Text] [Related]

  • 4. Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis.
    Korhonen R, Moilanen E.
    Basic Clin Pharmacol Toxicol; 2010 Jan; 106(1):13-21. PubMed ID: 19686542
    [Abstract] [Full Text] [Related]

  • 5. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
    Yukawa N, Mimori T.
    Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
    [Abstract] [Full Text] [Related]

  • 6. [Targeting CD20 in rheumatoid arthritis].
    Saito K, Tanaka Y.
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [Abstract] [Full Text] [Related]

  • 7. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab.
    Fleischmann RM.
    Semin Arthritis Rheum; 2009 Feb; 38(4):265-80. PubMed ID: 18336874
    [Abstract] [Full Text] [Related]

  • 8. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R, Albert D.
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [Abstract] [Full Text] [Related]

  • 9. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F, Isenberg DA.
    Handb Exp Pharmacol; 2008 Jan; (181):163-81. PubMed ID: 18071946
    [Abstract] [Full Text] [Related]

  • 10. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [Abstract] [Full Text] [Related]

  • 11. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application.
    Mease PJ.
    J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
    De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G.
    Arthritis Rheum; 2002 Aug; 46(8):2029-33. PubMed ID: 12209504
    [Abstract] [Full Text] [Related]

  • 13. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
    Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M.
    Scand J Immunol; 2004 Aug; 60(1-2):209-18. PubMed ID: 15238091
    [Abstract] [Full Text] [Related]

  • 14. Emerging therapeutics for rheumatoid arthritis.
    Bingham CO.
    Bull NYU Hosp Jt Dis; 2008 Aug; 66(3):210-5. PubMed ID: 18937634
    [Abstract] [Full Text] [Related]

  • 15. Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma.
    Panayi GS, Hainsworth JD, Looney RJ, Keystone EC.
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii18-ii20. PubMed ID: 15851523
    [Abstract] [Full Text] [Related]

  • 16. What is the role of rituximab in the treatment of rheumatoid arthritis?
    Atzeni F, Doria A, Turiel M, Sarzi-Puttini P.
    Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
    [Abstract] [Full Text] [Related]

  • 17. Ocrelizumab: a step forward in the evolution of B-cell therapy.
    Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ.
    Expert Opin Biol Ther; 2009 Jul; 9(7):889-95. PubMed ID: 19463076
    [Abstract] [Full Text] [Related]

  • 18. Targeting the B cell in rheumatoid arthritis.
    Cohen SB.
    Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):553-63. PubMed ID: 20732652
    [Abstract] [Full Text] [Related]

  • 19. B cell-directed therapy in rheumatoid arthritis--clinical experience.
    Panayi GS.
    J Rheumatol Suppl; 2005 Feb; 73():19-24; discussion 29-30. PubMed ID: 15693112
    [Abstract] [Full Text] [Related]

  • 20. Rituximab for the treatment of rheumatoid arthritis.
    Schuna AA.
    Pharmacotherapy; 2007 Dec; 27(12):1702-10. PubMed ID: 18041890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.